Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRLX101 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Daré Bioscience
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CRLX101 + paclitaxel is a combination investigational therapy targeting cancer. CRLX101 is a nanopharmaceutical comprised of camptothecin (CPT) conjugated to a cyclodextrin-based polymer, forming nanoparticles that deliver CPT directly into tumors. It acts primarily as a topoisomerase I inhibitor and can also inhibit HIF-1α (hypoxia-inducible factor-1 alpha). Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. The combination aims to improve anti-tumor efficacy through synergistic mechanisms: paclitaxel's cytotoxic activity and CRLX101's capability for sustained, tumor-targeted delivery of camptothecin. This regimen has been investigated in clinical trials for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer and other tumor types. Preclinical data suggest possible antiangiogenic effects and synergistic activity[1][3][5].
- Other names
- EP0057 + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))HIF1A (Hypoxia-inducible factor 1-alpha)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CRLX101 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRLX101 + paclitaxel.